ProCE Banner Activity

Phase I CHRYSALIS: Amivantamab, an EGFR-MET Bispecific Antibody, in Advanced NSCLC with MET Exon 14 Skipping Mutations

Slideset Download
Conference Coverage
Phase I results suggest promising clinical activity with amivantamab in unresectable or metastatic NSCLC driven by a MET exon 14 skipping mutation.

Released: September 23, 2021

Expiration: September 22, 2022

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bayer Healthcare Pharma

Daiichi Sankyo, Inc.

Janssen administered by Scientific Affairs

Janssen Pharmaceutica NV

Millennium Pharmaceuticals Inc Subsidary of Takeda

Regeneron Pharmaceuticals, Inc. and Sanofi Genzyme